在發(fā)達(dá)國(guó)家50歲以上的男性中,前列腺癌是被診斷出的最常見癌癥類型,。研究人員最近發(fā)現(xiàn)了與前列腺癌相關(guān)的基因變異,新成果發(fā)表在7月在線出版的《自然—遺傳學(xué)》期刊上,。與過去報(bào)告的易發(fā)性位點(diǎn)結(jié)合在一起,,新發(fā)現(xiàn)有可能解釋在前列腺癌的發(fā)生中占25%的家族性風(fēng)險(xiǎn)。
Rosalind Eeles和同事合作,報(bào)告了對(duì)4574位癌癥患者和4164位對(duì)照人員的泛基因組相關(guān)性分析結(jié)果,,以及這些研究結(jié)果在自30個(gè)國(guó)際研究小組的51311位受試者上的重復(fù),。他們鑒別出與前列腺癌易患性相關(guān)的7個(gè)新基因組區(qū)域。如今,,已鑒別出的前列腺癌易患性基因組位點(diǎn)超過了40個(gè),。(生物谷 Bioon.com)
生物谷推薦原文出處:
Nature Genetics doi:10.1038/ng.882
Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study
Zsofia Kote-Jarai, Ali Amin Al Olama, Graham G Giles,Gianluca Severi, Johanna Schleutker, Maren Weischer, Daniele Campa, Elio Riboli, Tim Key, Henrik Gronberg, David J Hunter, Peter Kraft, Michael J Thun, Sue Ingles, Stephen Chanock,Demetrius Albanes, Richard B Hayes, David E Neal,Freddie C Hamdy, Jenny L Donovan, Paul Pharoah,Fredrick Schumacher, Brian E Henderson,Janet L Stanford, Elaine A Ostrander,et.
Prostate cancer (PrCa) is the most frequently diagnosed male cancer in developed countries. We conducted a multi-stage genome-wide association study for PrCa and previously reported the results of the first two stages, which identified 16 PrCa susceptibility loci. We report here the results of stage 3, in which we evaluated 1,536 SNPs in 4,574 individuals with prostate cancer (cases) and 4,164 controls. We followed up ten new association signals through genotyping in 51,311 samples in 30 studies from the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) consortium. In addition to replicating previously reported loci, we identified seven new prostate cancer susceptibility loci on chromosomes 2p11, 3q23, 3q26, 5p12, 6p21, 12q13 and Xq12 (P = 4.0 × 10?8 to P = 2.7 × 10?24). We also identified a SNP in TERT more strongly associated with PrCa than that previously reported. More than 40 PrCa susceptibility loci, explaining ~25% of the familial risk in this disease, have now been identified.